Haemo-autologous Antegrade Repriming (HAR) as Minimum Impact Perfusion Strategy for Cardiopulmonary Bypass (HARjbm1)
Haemo-autologous Antegrade Repriming (HAR) Clinical Trial for Validation as Minimum Impact Perfusion Strategy in Cardiopulmonary Bypass
Sponsor: Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca
A NA clinical study on Anemia and Cardiac Disease, this trial is completed. The trial is conducted by Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca and has accumulated 7 data snapshots since 2018. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Mar 2021 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting NA
-
Jan 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Dec 2018 — Jan 2020 [monthly]
Recruiting NA
-
Nov 2018 — Dec 2018 [monthly]
Recruiting NA
First recorded
Aug 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca
- Juan Blanco Morillo
For direct contact, visit the study record on ClinicalTrials.gov .